The cistrome refers to "the set of cis-acting targets of a trans-acting factor on a genome-wide scale, also known as the in vivo genome-wide location of [transcription factor binding-sites] or histone modifications". The term cistrome is a portmanteau of cistr (from cistron) + ome (from genome). The term cistrome was coined by investigators at the Dana-Farber Cancer Institute and Harvard Medical School.
Technologies such as chromatin immunoprecipitation combined with microarray analysis "ChIP-on-chip" or with massively parallel DNA sequencing "ChIP-Seq" have greatly facilitated the definition of the cistrome of transcription factors and other chromatin associated proteins.
- Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, Pape UJ, Poidinger M, Chen Y, Yeung K, Brown M, Turpaz Y, Liu XS (2011). "Cistrome: an integrative platform for transcriptional regulation studies". Genome Biol. 12 (8): R83. doi:10.1186/gb-2011-12-8-r83. PMC 3245621. PMID 21859476.
- "cistrome / FrontPage". PBWiki, Inc.
- Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M (March 2008). "FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription". Cell. 132 (6): 958–70. doi:10.1016/j.cell.2008.01.018. PMC 2323438. PMID 18358809.
- Lupien M, Brown M (June 2009). "Cistromics of hormone-dependent cancer". Endocr. Relat. Cancer. 16 (2): 381–9. doi:10.1677/ERC-09-0038. PMID 19369485.
|This genetics article is a stub. You can help Wikipedia by expanding it.|